Back to top
more

Dynavax Technologies (DVAX)

(Delayed Data from NSDQ)

$10.33 USD

10.33
4,776,516

-0.73 (-6.60%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $10.33 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

AstraZeneca's (AZN) Capivasertib Gets FDA Nod for Breast Cancer

by Zacks Equity Research

AstraZeneca's (AZN) capivasertib gets approval in combination with Faslodex for HR-positive, HER2-negative metastatic breast cancer.

Zacks Equity Research

Chemomab (CMMB) Up on Fast Track Designation to CM-101 for PSC

by Zacks Equity Research

The FDA bestows Fast Track designation to Chemomab's (CMMB) pipeline candidate, CM-101, for the treatment of primary sclerosing cholangitis. Stock rises.

Zacks Equity Research

CRISPR (CRSP), Vertex Get UK Nod for First Gene Therapy Casgevy

by Zacks Equity Research

CRISPR (CRSP) and Vertex's Casgevy, the first-ever gene-edited therapy, to treat sickle cell disease and transfusion-dependent beta thalassemia gets MHRA nod. Stock rises in pre-market trading.

Zacks Equity Research

Bristol Myers (BMY) Receives FDA Approval for NSCLC Drug

by Zacks Equity Research

Bristol Myers' (BMY) repotrectinib, a tyrosine kinase inhibitor (???TKI???) targeting ROS1 oncogenic fusions, gets FDA???s approval for NSCLC.

Zacks Equity Research

Rocket (RCKT) Surges 40% in 3 Months on Regulatory Updates

by Zacks Equity Research

Rocket (RCKT) gains 40% in three months on positive regulatory updates on its key candidates.

Zacks Equity Research

Intellia (NTLA) Rises on EC's Orphan Drug Tag for HAE Candidate

by Zacks Equity Research

The European Commission bestows orphan drug designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, for treating hereditary angioedema. Stock rises.

Zacks Equity Research

AstraZeneca's (AZN) Imfinzi Early-Stage Lung Cancer Study Fails

by Zacks Equity Research

AstraZeneca's (AZN) PACIFIC-2 study on Imfinzi fails to achieve statistical significance for the primary endpoint of progression-free survival.

Zacks Equity Research

Roche (RHHBY) Tecentriq SC Receives Positive CHMP Opinion

by Zacks Equity Research

Roche's (RHHBY) subcutaneous (SC) formulation of immuno-oncology drug Tecentriq gets CHMP's positive recommendation for all approved indications.

Zacks Equity Research

Alkermes (ALKS) Proprietary Drugs Aid Growth Amid Competition

by Zacks Equity Research

Alkermes' (ALKS) growth is being driven by the sale of its proprietary products, Vivitrol, Aristada and Lybalvi. However, stiff competition in the target market remains an overhang.

Zacks Equity Research

Novo Nordisk's (NVO) Wegovy Positive in Cardiovascular Study

by Zacks Equity Research

Novo Nordisk's (NVO) obesity drug Wegovy shows potential in cardiovascular study beyond the benefits of associated weight loss.

Zacks Equity Research

Pacira (PCRX) Gets FDA Nod for Exparel's Label Expansion

by Zacks Equity Research

The FDA approves Pacira's (PCRX) supplemental new drug application to expand the label of Exparel to include both sciatic and femoral nerve blocks.

Zacks Equity Research

Beam Therapeutics (BEAM) Q3 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Beam Therapeutics' (BEAM) third-quarter 2023 earnings and revenues surpass expectations. The company focuses on developing genome-editing candidate, BEAM-101.

Zacks Equity Research

Amicus' (FOLD) Q3 Loss Narrows, Galafold Sales View Updated

by Zacks Equity Research

Amicus (FOLD) incurs a narrower-than-expected loss in the third quarter. However, revenues beat estimates. The company tightens Galafold revenue guidance for 2023.

Zacks Equity Research

Viatris (VTRS) Q3 Earnings Beat, Complex Generics Sales Dip

by Zacks Equity Research

Viatris (VTRS) third-quarter earnings beat estimates. While brands maintain business, the Complex generics business performs below management's expectations.

Zacks Equity Research

Nektar Therapeutics (NKTR) Incurs Wider-Than-Expected Q3 Loss

by Zacks Equity Research

Nektar (NKTR) misses third-quarter estimates for the bottom line but beats the same for the top line.

Zacks Equity Research

Theravance's (TBPH) Q3 Loss Narrows, Revenues Beat Marginally

by Zacks Equity Research

Thervance (TBPH) incurs a narrower-than-expected loss in the third quarter of 2023. Revenues marginally beat estimates.

Zacks Equity Research

Biogen (BIIB) Beats on Q3 Earnings & Sales, Cuts EPS View

by Zacks Equity Research

Biogen (BIIB) beats third-quarter estimates for earnings and sales. It lowers its 2023 EPS guidance range to include the impact of dilution from the Reata acquisition. Stock rises in pre-market.

Zacks Equity Research

Gilead (GILD) Q3 Earnings Beat, Trodelvy Fuels Oncology Sales

by Zacks Equity Research

Gilead (GILD) reports better-than-expected results for the third quarter as Trodelvy boosts oncology sales and Biktarvy maintains momentum in the HIV franchise.

Zacks Equity Research

bluebird (BLUE) Q3 Earnings Top; Zynteglo, Skysona Fuel Sales

by Zacks Equity Research

bluebird bio (BLUE) reports better-than-expected results in the third quarter of 2023 due to product revenues now being generated from Skysona (elivaldogene autotemcel) and Zynteglo (betibeglogene autotemcel).

Zacks Equity Research

Axsome (AXSM) Q3 Loss Widens, Revenues Surpass Estimates

by Zacks Equity Research

Axsome (AXSM) incurs a wider-than-expected loss in the third quarter of 2023 while sales beat estimates. The company's shares declined post earnings announcement.

Zacks Equity Research

Is Dynavax Technologies (DVAX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Dynavax Technologies (DVAX) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Zacks Equity Research

Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus

by Zacks Equity Research

Editas' (EDIT) third-quarter 2023 results reflect a year-over-year increase in revenues. The stock of the company rises 18%.

Zacks Equity Research

Bausch Health (BHC) Q3 Earnings & Sales Beat, '23 View Updated

by Zacks Equity Research

Bausch (BHC) surpasses third-quarter earnings and sales estimates as most of the business units post growth.

Zacks Equity Research

Intra-Cellular (ITCI) Q3 Earnings Top, Product Sales View Raised

by Zacks Equity Research

Intra-Cellular (ITCI) third-quarter 2023 earnings and revenues beat estimates. Caplyta sales continue to drive growth. The company raises its guidance for full-year 2023 Caplyta sales.

Zacks Equity Research

ImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives Revenues

by Zacks Equity Research

ImmunoGen's (IMGN) third-quarter 2023 earnings and revenues surpass estimates, driven by strong adoption of its sole-marketed drug Elahere. The company reiterates its revenue guidance.